Intelligence Feed event · Policy · 2026-10-01

    Survodutide Delivers 13.1% Weight Loss in Phase III Diabetes and Obesity Trial

    Question

    Survodutide Delivers 13.1% Weight Loss in Phase III Diabetes and Obesity Trial

    Direct answer

    Boehringer Ingelheim and Zealand Pharma announced headline efficacy figures from their 76-week SYNCHRONIZE-2 Phase III study evaluating survodutide. The dual-mechanism candidate met primary endpoints in an obesity and type 2 diabetes cohort, generating a mean 13.1% reduction in weight alongside improved glycemic markers relative to a 3.1% placebo response. The data positions survodutide in the commercial competitive landscape for metabolic therapeutics, validating Zealand Pharma's dual agonist pipeline and setting up global regulatory filing timelines.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-01
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Survodutide Delivers 13.1% Weight Loss in Phase III Diabetes and Obesity Trial”, revision 1, evidence through 2026-10-01. https://marketontology.com/market-events/2026-10-01/survodutide-delivers-13-1-weight-loss-in-phase-iii-diabetes-and-obesity-trial-c3fa96

    POLICY
    Survodutide Delivers 13.1% Weight Loss in Phase III Diabetes and Obesity Trial
    Boehringer Ingelheim and Zealand Pharma announced headline efficacy figures from their 76-week SYNCHRONIZE-2 Phase III study evaluating survodutide. The dual-mechanism candidate met primary endpoints in an obesity and type 2 diabetes cohort, generating a mean 13.1% reduction in weight alongside improved glycemic markers relative to a 3.1% placebo response. The data positions survodutide in the commercial competitive landscape for metabolic therapeutics, validating Zealand Pharma's dual agonist pipeline and setting up global regulatory filing timelines.
    ZLDPY
    Impact
    77
    OCT 1
    SIG
    90%
    ZLDPY
    Survodutide Delivers 13.1% Weight Loss in Phase III Diabetes and Obesity Trial
    Boehringer Ingelheim and Zealand Pharma announced headline efficacy figures from their 76-week SYNCHRONIZE-2 Phase III study evaluating survodutide. The dual-mechanism candidate met primary endpoints in an obesity and type 2 diabetes cohort, generating a mean 13.1% reduction in weight alongside improved glycemic markers relative to a 3.1% placebo response. The data positions survodutide in the commercial competitive landscape for metabolic therapeutics, validating Zealand Pharma's dual agonist pipeline and setting up global regulatory filing timelines.
    → Statistically significant Phase III dual agonist efficacy clears commercial pathway toward regulatory submission, driving royalty valuation for partner ZLDPY.
    Impact
    Boehringer Ingelheim and Zealand Pharma announced headline efficacy figures from their 76-week SYNCHRONIZE-2 Phase III study evaluating survodutide. The dual-mechanism candidate met primary endpoints in an obesity and type 2 diabetes cohort, generating a mean 13.1% reduction in weight alongside improved glycemic markers relative to a 3.1% placebo response. The data positions survodutide in the commercial competitive landscape for metabolic therapeutics, validating Zealand Pharma's dual agonist pipeline and setting up global regulatory filing timelines.
    Affected
    ZLDPY
    Transmission
    Statistically significant Phase III dual agonist efficacy clears commercial pathway toward regulatory submission, driving royalty valuation for partner ZLDPY.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ZLDPYbiotech pipeline derisking and future commercial royalty streams on survodutideUp1-5dZealand Pharma announced positive Phase III SYNCHRONIZE-2 trial results.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month